Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Phase 1/2 study of pacritinib, a JAK2/FLT3 inhibitor of the next generation, in myelofibrosis or other myeloid malignancies.